Skip to main content
Signal8

NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development

$ELABPress releaseNov 5, 2026, 7:31 AM ET

PMGC Holdings' subsidiary NorthStrive Biosciences completed an eight-week preclinical study of EL-32, an engineered probiotic targeting muscle preservation, in combination with semaglutide in a diet-induced obesity mouse model. Findings were mixed: the highest-dose combination showed statistically significant greater absolute lean mass and weight reduction versus semaglutide alone, but effects were not consistent across doses, and EL-32 monotherapy showed no meaningful benefit.

Key figures

Drug Name
EL-32
Phase Of Trial
Preclinical (DIO mouse model)
Study duration weeks
8

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.